Locally Advanced Basal Cell Carcinoma with Intraocular Invasion
AbstractWe present a 103 - year - old patient, with duration of complaints of about ten years. The initial complaint had been presented as a small nodule, located on the eyebrow, which subsequently ulcerated and encompassed larger regions of the upper and lower eyelids. For the past three years, the patient also had complaints of a worsening of his vision, without seeking for medical help. Within the dermatological examination, an intraocular and periocular localised tumour was established, characterised by a raised peripheral edge and central ulceration. More careful examination revealed that the bulb was fully consumed. The patient refused further diagnosis and treatment. Advanced basal cell carcinomas with intraocular invasion are rare in general. If the patient refuses surgery, radiotherapy and systemic therapy with modern medications such as Vismodegib or Sonidegib are available as treatment options.
Plum Analytics Artifact Widget Block
Malec K, Brzewski P, Cenda P, Kuchta K, GasiÅ„ski M, Wojas-Pelc A, Modrzejewski M. Extensive, neglected basal cell carcinoma of the half of the face-surgical treatment and reconstruction with an anterolateral microvascular thigh flap. Postepy Dermatol Alergol. 2016; 33(3):235-8. https://doi.org/10.5114/ada.2016.60618 PMid:27512361 PMCid:PMC4969421
Lovatt TJ, Lear JT, Bastrilles J, et al. Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumours. J Am Acad Dermatol. 2005; 52:468â€“73. https://doi.org/10.1016/j.jaad.2004.08.060 PMid:15761425
Migden M. R., Guminski A., Gutzmer R., et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. The Lancet Oncology. 2015; 16(6):716â€“728. https://doi.org/10.1016/S1470-2045(15)70100-2
Food and Drug Administration (FDA) FDA approves new treatment for most common form of advanced skin cancer. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm.
European Medicines Agency (EMA) Assessment report: odomzo. EMEA/H/C/002839/0000.2015,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002839/WC500192972.pdf.
Sekulic A., Migden M. R., Oro A. E., et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. The New England Journal of Medicine. 2012; 366(23):2171â€“2179. https://doi.org/10.1056/NEJMoa1113713 PMid:22670903 PMCid:PMC5278761
European Medicines Agency (EMA) Assessment report: erivedge. EMEA/H/C/002602. 2013,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/002602/WC500146820.pdf.
All rights reserved.